Dogwood Therapeutics, Inc.
DWTX
$6.21
-$0.01-0.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 128.78% | 200.18% | 167.76% | 133.84% | 16.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 444.45% | 279.38% | 194.85% | 124.48% | -8.99% |
| Operating Income | -444.45% | -279.38% | -194.85% | -124.48% | 8.99% |
| Income Before Tax | -564.04% | -424.65% | -329.81% | -133.19% | 8.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -567.33% | -428.72% | -333.55% | -133.18% | 8.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -567.33% | -428.72% | -333.55% | -133.18% | 8.22% |
| EBIT | -444.45% | -279.38% | -194.85% | -124.48% | 8.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -295.24% | -219.94% | -168.48% | -57.83% | 25.17% |
| Normalized Basic EPS | -205.68% | -123.70% | -83.91% | -52.29% | 25.17% |
| EPS Diluted | -295.24% | -219.94% | -168.48% | -57.83% | 25.17% |
| Normalized Diluted EPS | -205.68% | -123.70% | -83.91% | -52.29% | 25.17% |
| Average Basic Shares Outstanding | 84.54% | 79.28% | 57.13% | 36.73% | 20.23% |
| Average Diluted Shares Outstanding | 84.54% | 79.28% | 57.13% | 36.73% | 20.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |